Trials / Completed
CompletedNCT00790127
Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
A Multi-National, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HQK-1001 in Subjects With Beta Thalassemia Intermedia, Including Hemoglobin E Beta Thalassemia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- HemaQuest Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered daily for 8 weeks in subjects with beta thalassemia intermedia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HQK-1001 | HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days |
| DRUG | Placebo | Matching placebo capsules administered once a day, orally, for 56 days |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2008-11-13
- Last updated
- 2011-05-20
Locations
2 sites across 2 countries: Lebanon, Thailand
Source: ClinicalTrials.gov record NCT00790127. Inclusion in this directory is not an endorsement.